Taevas
United StatesMedical Devices
Market Intelligence
Market Intelligence for Medical Devices in United States
Navigate FDA regulatory pathways, size your addressable market, and identify the right entry strategy with intelligence built specifically for medical devices companies entering the United States. Taevas Global transforms complex market data into clear, a
Market
United States
Industry
Medical Devices
Service
Market Intelligence
Regulator
FDA Center for Devices and Radiological Health (CDRH)
Timeline
4-6 Weeks
What We Deliver
Six Pillars of United States Medical Devices Intelligence
Our six interconnected intelligence pillars cover every dimension a medical devices company needs to enter, compete, and grow in the United States market with confidence.
01
Market Sizing and Demand Analysis
We quantify the total addressable, serviceable addressable, and serviceable obtainable markets for your specific device category across the United States. Our analysis incorporates procedure volume data, hospital and ambulatory care utilization trends, and payer coverage patterns to give you a defensible revenue opportunity estimate. This foundation underpins every strategic decision that follows.
TAM, SAM, and SOM sizing by device category and care setting
Procedure volume trends across hospital, ASC, and outpatient channels
Payer mix and reimbursement coverage mapping by geography
How It Works
From Brief to Board-Ready Intelligence
Our four-stage engagement is designed to move from your initial brief to a fully validated, decision-ready intelligence package in six weeks or less.
Step 1 · Day 1-2
Discovery and Scoping
We begin with a structured discovery session to understand your device category, intended use, target customer segments, and strategic objectives for the United States market. This session allows us to define the precise scope of the intelligence engagement, agree on key research questions, and align on deliverable formats that match your internal decision-making process. A signed scope document is produced within 48 hours.
Taevas Approach
The discovery session typically runs 90 minutes and involves your regulatory, commercial, and strategy leads. We use a proprietary scoping framework developed specifically for medical devices market entry to ensure no critical intelligence gap is missed. Output is a detailed scope-of-work document with research questions, data sources, and a confirmed delivery timeline.
Market Snapshot
United States Medical Devices Market at a Glance
$0B
U.S. Medical Devices Market Size (2023)
0%
Projected Annual Market Growth Rate
0+
FDA-Registered Device Manufacturers
0+
510(k) Clearances Issued Annually
World's Largest Single Medical Devices Market
The United States accounts for approximately 40 percent of global medical devices sales, making it the single most important market for any device manufacturer with global ambitions. Demand is driven by an aging population, high rates of chronic disease, and a healthcare system that consistently adopts new technology faster than any other major economy. Per-capita medical device spending in the United States is more than double that of Western Europe.
FDA CDRH Remains the World's Most Scrutinized Regulator
The FDA's Center for Devices and Radiological Health oversees the classification, clearance, and approval of all medical devices marketed in the United States, and its decisions set a global benchmark that other regulators frequently reference. The 510(k) pathway, which requires demonstration of substantial equivalence to a legally marketed predicate device, accounts for the majority of device clearances each year. Manufacturers must also comply with Quality System Regulation requirements under 21 CFR Part 820, which is being updated to align with ISO 13485.
Reimbursement Complexity is the Primary Market Access Barrier
Securing FDA clearance or approval is a necessary but not sufficient condition for commercial success in the United States. Devices must also obtain favorable coding, coverage, and payment determinations from CMS and commercial payers, a process that can add 12 to 36 months to the timeline for novel technologies. Companies that invest in reimbursement strategy early, including clinical evidence generation aligned to payer requirements, consistently outperform those that treat it as an afterthought.
Digital Health and AI-Enabled Devices Are Reshaping the Landscape
The FDA has issued a growing body of guidance on Software as a Medical Device and AI and machine learning-based medical devices, reflecting a fundamental shift in what constitutes a medical device in the United States. The number of AI-enabled device authorizations has grown rapidly, with the FDA having authorized over 950 AI and ML-enabled devices as of 2024. Companies entering the United States market with digital or AI-enabled products must navigate both traditional device regulatory pathways and emerging software-specific requirements.
What's Included
Everything in Your Report
Every Market Intelligence engagement for Medical Devices in the United States produces eight structured deliverables designed to support decisions from regulatory strategy through commercial launch.
Market Sizing Report
A fully documented TAM, SAM, and SOM analysis for your device category in the United States, including methodology, data sources, and scenario-based projections for conservative, base, and optimistic growth cases.
FDA Regulatory Pathway Memo
A concise regulatory strategy document identifying the most appropriate FDA pathway for your device, key submission requirements, predicate device analysis, and a realistic timeline and cost estimate for clearance or approval.
Competitive Intelligence Dossier
Detailed profiles of the top 8 to 12 competitors in your device segment, covering product portfolios, pricing, market share estimates, clinical evidence positioning, distribution strategies, and recent strategic moves.
Reimbursement Landscape Analysis
A structured assessment of existing CMS coding and payment frameworks applicable to your device, commercial payer coverage policies across major insurers, and a reimbursement risk and opportunity matrix to inform your market access strategy.
Regional Opportunity Heat Map
A geographic analysis identifying the highest-priority United States regions and metropolitan statistical areas for initial market entry, based on procedure volume, payer mix, competitive density, and key account concentration.
Channel and Distribution Assessment
An evaluation of distribution channel options including direct sales, independent distributors, and GPO contracting, with economics, coverage trade-offs, and a recommended go-to-market channel architecture for your device category.
Stakeholder and KOL Mapping
Identification of the key opinion leaders, clinical champions, professional societies, and hospital system decision-makers who carry the most influence over adoption decisions in your device category across the United States.
Strategic Recommendations Deck
An executive-ready PowerPoint presentation synthesizing all findings into a prioritized set of strategic recommendations, including a phased market entry roadmap, risk register, and suggested next steps for your leadership team.
Who This Is For
Built for These Situations
Market Entry
International Medical Devices Manufacturer Entering the United States
You have a cleared or approved device in your home market and are evaluating whether and how to enter the United States. You need to understand FDA requirements, assess the competitive landscape, and determine whether the reimbursement environment supports a viable business case before committing significant capital. The United States market is attractive but complex, and you cannot afford to learn by trial and error.
Outcome
A clear go or no-go decision framework backed by validated market data, a defined FDA regulatory pathway, and a realistic commercial launch plan.
Next Steps
After Market Intelligence, Most Clients Move To
FAQ
Common Questions
Get Started
Ready to Map Your United States Opportunity?
Get the FDA regulatory clarity, competitive landscape intelligence, and reimbursement analysis you need to make confident decisions about the United States medical devices market. Request a proposal and receive a tailored scope within 48 hours.
Delivered in 4-6 weeks with a 30-day post-delivery support window
Built on FDA CDRH data, CMS claims data, and validated primary research
Led by senior analysts with medical devices sector expertise
Structured for board presentations and investment committee reviews